EP
AUTL

Eversept Partners’s Autolus Therapeutics AUTL Stock Holding History

Eversept Partners’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-610,231
Closed -$1.39M – 89
2025
Q2 		$1.39M Buy
610,231
+266,284
+77% +$440K 0.13% 58
2025
Q1 		$533K Buy
343,947
+245,052
+248% +$497K 0.05% 56
2024
Q4 		$232K Sell
98,895
-307,663
-76% -$1.04M 0.02% 65
2024
Q3 		$1.48M Sell
406,558
-204,344
-33% -$815K 0.1% 61
2024
Q2 		$2.13M Buy
+610,902
New +$2.64M 0.15% 64
2022
Q2 		– Sell
-371,540
Closed -$1.55M – 82
2022
Q1 		$1.55M Sell
371,540
-30,000
-7% -$126K 0.12% 65
2021
Q4 		$2.08M Buy
401,540
+3,466
+0.9% +$20.8K 0.13% 79
2021
Q3 		$2.61M Sell
398,074
-75,000
-16% -$474K 0.18% 68
2021
Q2 		$3.14M Buy
+473,074
New +$2.94M 0.21% 57
2021
Q1 		– Sell
-154,981
Closed -$1.39M – 90
2020
Q4 		$1.39M Buy
+154,981
New +$1.65M 0.16% 47
2020
Q3 		– Sell
-258,360
Closed -$4.14M – 52
2020
Q2 		$4.14M Buy
258,360
+48,347
+23% +$536K 0.57% 32
2020
Q1 		$1.26M Buy
+210,013
New +$1.94M 0.31% 37

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners's AUTL Position: Q3 2025 in Review

Eversept Partners sold out of Autolus Therapeutics (AUTL) in Q3 2025, closing a stake of 610,231 shares — an estimated $1.39M sold.

Eversept Partners first reported a position in AUTL in Q1 2020 and held it in 12 quarters. The position peaked at $4.14M in Q2 2020. 96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

  • Eversept Partners reported no remaining Autolus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Eversept Partners sold 610,231 Autolus Therapeutics shares in Q3 2025, an estimated $1.39M.
  • Eversept Partners first reported a position in Autolus Therapeutics in Q1 2020 and held it in 12 quarters.
  • Eversept Partners's Autolus Therapeutics position peaked at $4.14M in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.